Article
CD133 Expression in Medullary Thyroid Cancer Cells Identifies Patients with Poor Prognosis.
The Journal of clinical endocrinology and metabolism - 1 Nov 2020
Cordero-Barreal Alfonso, Caleiras Eduardo, López de Maturana Evangelina, Monteagudo María, Martínez-Montes Ángel M, Letón Rocío, Gil Eduardo, Álvarez-Escolá Cristina, Regojo Rita M, Andía Víctor, Marazuela Mónica, Guadalix Sonsoles, Calatayud María, Robles-Díaz Luis, Aguirre Miguel, Cano Juana M, Díaz José Ángel, Saavedra Pilar, Lamas Cristina, Azriel Sharona, Sastre Julia, Aller Javier, Leandro-García Luis J, Calsina Bruna, Roldán-Romero Juan María, Santos María, Lanillos Javier, Cascón Alberto, Rodríguez-Antona Cristina, Robledo Mercedes, Montero-Conde Cristina
Abstract excerpt
CONTEXT: The identification of markers able to determine medullary thyroid cancer (MTC) patients at high-risk of disease progression is critical to improve their clinical management and outcome. Previous studies have suggested that expression of the stem cell marker CD133 is associated with MTC aggressiveness. OBJECTIVE: To evaluate CD133 impact on disease progression in MTC and explore the regulatory mechanisms...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
